Advertisement

Reactions Weekly

, Volume 1695, Issue 1, pp 221–221 | Cite as

Inotuzumab ozogamicin

Acute cholecystitis: case report
Case report
  • 13 Downloads

Reference

  1. Khouri IF, et al. Safety of addition of inotuzumab ozogamicin (CMC 544) to bendamustine, fludarabine, and rituximab (BFR) allogeneic conditioning for lymphoid malignancies. Blood 130 (Suppl. 1): 3240, 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/3240 [abstract] -USA

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations